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Abstract 
 
BACKGROUND & AIMS: There is a close relationship between hepatitis C virus 
(HCV) infection and lichen planus, a chronic inflammatory muco-cutaneous 
disease. We performed a genome-wide association study (GWAS) to identify 
genetic variants associated with HCV-related lichen planus. 
 
METHODS: We conducted a GWAS of 261 patients with HCV infection treated 
at a tertiary medical center in Japan from October 2007 through January 2013; 
71 had lichen planus and 190 had normal oral mucosa. We validated our 
findings in a GWAS of 38 patients with HCV-associated lichen planus and 7 
HCV-infected patients with normal oral mucosa treated at a medical center in 
Italy. 
 
RESULTS: Single-nucleotide polymorphisms (SNPs) in NRP2 (rs884000) and 
IGFBP4 (rs538399) were associated with risk of HCV-associated lichen planus 
(P<1x10–4). We also found an association between a SNP in the HLA-DR/DQ 
genes (rs9461799) and susceptibility to HCV-associated lichen planus. The 
odds ratios for the minor alleles of rs884000, rs538399, and rs9461799 were 
3.25 (95% CI, 1.95–5.41), 0.40 (95% CI, 0.25–0.63), and 2.15 (95% CI, 1.41–
3.28), respectively. 
 
CONCLUSION: In a GWAS of Japanese patients with HCV infection, we 
replicated associations between previously reported polymorphisms in HLA 
class II genes and risk for lichen planus. We also identified SNPs in NRP2 and 
IGFBP4 loci that increase and reduce risk of lichen planus, respectively. These 
genetic variants might be used to identify patients with HCV infection who are at 
risk for lichen planus. 
 
KEY WORDS: inflammation, risk factor, oral mucosa, autoimmunity 
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INTRODUCTION 
Lichen planus (LP) (see Figure 1 below) is a common, chronic inflammatory 
mucocutaneous disease that affects mainly middle-aged adults, the prevalence 
being greater among women. The oral mucosa, skin, genital mucosa, and nails 
are commonly involved, in any combination. The clinical features of oral lichen 
planus (OLP) are generally polymorphic and usually consist of bilateral and/or 
multiple symmetrical lesions, such as reticular, plaque-like, papular, atrophic, 
erosive and bullous, and these are categorized into six types 1. In particular, 
erosive and atrophic forms of OLP manifest painful symptoms, with weight loss 
and poor quality of life, and have the potential of malignant transformation 2, 3. 
 
OLP is a T cell-mediated autoimmune disease in which autocytotoxic CD8+ T 
cells trigger apoptosis of oral epithelial cells 4. The cytotoxic activity of CD8+ 
lesional T cell clones may be blocked partially by anti-MHC Class I monoclonal 
antibody 5.   
 
The cause of OLP is unknown, but it seems to be triggered by stress, genetics, 
allergic reactions to medicines or dental materials, and by viral infections such 
as with hepatitis C virus (HCV) 6. It has been shown that chronic HCV infection, 
in addition to causing liver disease, is responsible for several extrahepatic 
manifestations and immune abnormalities, including hematologic, renal, and 
mucocutaneous diseases 7-9. Replication of HCV in the oral mucosa 10 and 
presence of HCV-specific T cells in OLP specimens 11, 12 could be involved in the 
pathogenesis of OLP. Three recent independent meta-analyses provide robust 
evidence that LP and HCV are associated 13-15.  
 
In particular, the relationship between OLP and HCV has been suggested by 
studies from Japan and Mediterranean countries, indicating a strong geographic 
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relationship 16, 17. The differences with respect to geographic area could be 
associated with the different genetic susceptibility of the hosts. HCV-associated 
OLP may be subdivided into distinct subtypes, because studies have shown an 
increased frequency of the Human Leucocyte Antigens (HLA) class II allele 
group, DR6, in OLP patients with HCV compared to those without HCV 18, 19 
(52% vs. 18%, P=0.028, relative risk=4.93). The HLA-DR6 allele group is 
frequently observed in Italian patients with OLP and hepatitis C. 
 
HCV infection is a major public health problem because it causes chronic 
hepatitis, cirrhosis and hepatocellular carcinoma (HCC). In Japan, elderly 
patients are at a higher risk for HCC, and HCV eradication has a smaller effect 
on hepatocarcinogenesis in older patients 20. OLP can appear or be exacerbated 
during interferon (IFN) therapy for chronic hepatitis C 21, 22.  
 
The genome-wide association study (GWAS) has become a powerful tool for 
investigating the human genetic basis of various diseases. Various 
genome-based host variants, such as IFNL3 (also known as IL28B) 23-25 and 
inosine triphosphatase (ITPA) 26 genes, have been found to be valuable markers 
for treatment response to hepatitis C and predicting spontaneous viral 
clearance.   
 
The purpose of this study was to identify the host genetic factors for HCV-related 
LP in the Japanese and Italian populations. 
 
MATERIALS and METHODS 
Ethical considerations 
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The study protocol conformed to the ethical guidelines of the 1975 Declaration 
of Helsinki and was approved by the ethics committee of Saga Medical School, 
Kurume Medical School, and each participating medical center. Written 
informed consent for participation in the study was obtained from each patient 
and all samples were anonymized. All the applied methods in this study were 
carried out in accordance with the approved guidelines. 
 
Study group and samples 
Genomic DNA samples were collected from HCV-infected Japanese patients 
with LP (71 patients; mean age ± SD, 67.2 ± 9.6 years; men/women 24/47) 
and HCV-infected Japanese patients with normal oral mucosa (190 patients; 
mean age ± SD, 59.8 ± 10.0 years; men/women 83/107) who consulted 
Kurume University School of Medicine, Fukuoka, Japan from October 30, 
2007 to January 22, 2013 (Table 1). OLP had been diagnosed clinically and 
histopathologically. The sites of LP in the subjects included: oral mucosa 
(n=65), oral and genital mucosa (n=1), oral mucosa and skin (n=3), and skin 
(n=2).  
 
Moreover, a replication study was performed using Italian individuals (38 
patients with LP and 7 patients with normal oral mucosa) who consulted 
Regional Transplantation Center, Piedmont, Molinette Hospital,Turin, Italy. 
 
Genomic DNA was extracted from the peripheral blood of a total of 261 
Japanese HCV-infected patients using the QIAamp DNA Blood Midi kit 
(Qiagen, Tokyo, Japan) in the Department of Virology, Liver Unit, Nagoya City 
University Graduate School of Medical Sciences. One microgram of purified 
genomic DNA was dissolved in 100 µl of TE buffer (pH 8.0) (Wako, Osaka, 
Japan), followed by storage at -20°C until use. 
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Evaluation of liver diseases in Japanese patients  
A total of 261 subjects were tested for their liver function. Anti-HCV was 
measured using a chemiluminescent enzyme immunoassay kit (Lumipulse II 
HCV, Fujirebio, Tokyo, Japan) and HCV RNA in serum was analyzed by 
quantitative PCR assay (COBAS AMPLICOR HCV MONITOR v 2.0 Test, 
COBAS AmpliPrep/COBAS Taq-Man HCV Test, Roche Molecular Systems, 
Branchburg, New Jersey, US). Ultrasonographic examination was performed 
on all patients. Computed tomography (CT), liver biopsy and endoscopic 
examination for esophageal or gastric varices were performed on some 
patients. We used other possible predictors of liver cirrhosis progression, 
including serum albumin, total bilirubin, prothrombin time, and platelet count.  
 
 SNP genotyping and data cleaning  
 
We genotyped 261 HCV-infected patients with or without LP using the 
Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc., Santa Clara, 
CA), in accordance with the manufacturer’s instructions. The genotype calls 
for 900K SNPs were determined using the Genotyping Console v4.1 software 
(with Birdseed v1 algorithm) and all samples passed a heterozygosity check. 
No duplication or related samples were identified by identity by descent testing. 
A principal component analysis was performed using 261 studied samples 
together with HapMap samples (including 43 JPT, 40 CHB, 91 YRI, and 91 
CEU samples) (Supplementary FigureS1). The cluster of studied samples 
showed overlap with that of HapMap-JPT. The average sample call rate for the 
261 studied samples was 98.82% (95.26-99.55%). Low-quality genotype data 
were excluded by the following thresholds for quality control; SNP call rate 
<95%, MAF <1% and HWE P value <0.0001. A total of 629,588 SNPs passed 
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the threshold. The scatter plots for SNP with P <0.0001 in the allelic model 
were then checked by visual inspection and thirty-five SNPs were excluded 
from further analysis. Finally, a total of 629,553 SNPs were used for further 
statistical analyses. 
A replication study was conducted in Italian individuals for three SNPs 
(HLA-DR/DQ rs9461799, IGFBP4 rs538399, and NRP2 rs884000) using 
TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) 
on a LightCycle 480 Real-Time PCR System (Roche, Mannheim, Germany). 
 
SNP Imputation 
 
Unobserved genotypes were imputed using the phased genotype data of 
1000 Genomes Project reference data (Integrated Phase 3, June 2014 
released) with standard software packages such as IMPUTE version 2 
(IMPUTE2) with default parameters. GTOOL was used for data format 
conversion from PLINK format to IMPUTE2 format. A 1-Mb window size 
centered on each candidate SNP was applied to impute. After imputation, the 
results of association test for imputed data were obtained using PLINK 1.07. 
SNPs with >1% missing genotype data, HWE P value ≥0.001 and samples 
including >10% missing genotype were eliminated. 
 
Statistical analysis 
 
For the association tests, P values, ORs and 95% CIs between the SNP and 
disease phenotype were assessed by chi-squared test with a two-by-two 
contingency table for the allelic model. To avoid false-positive results due to 
multiple testing, the significance level for the GWAS was set at P = 5×10-8. As 
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sensitive analysis, logistic regression analysis with additive genetic model and 
gender and age as covariates was implemented. 
 
RESULTS 
Genome-wide association analysis 
 
Figure 2 (Manhattan Plot) shows a genome-wide view of single point 
associations of 629,553 SNPs, based on allele frequencies in a comparison of 
71 HCV patients with LP and 190 HCV patients without OLP. A 
quantile-quantile plot of the distribution of test statistics for the comparison of 
allele frequencies between the two groups showed that the inflation factor 
lambda was 1.027 for all the tested SNPs, and 1.024 when SNPs in the HLA 
region (chr6: 29,645,000-33,365,000, GRCh37 hg19) were excluded 
(Supplementary Figure S2). Although no SNPs reached the genome-wide 
significant level (i.e. P <5×10-8), the greatest hit association was observed for 
rs884000, which is located about 17.5 kb downstream from the NRP2 
(neuropilin-2) gene, showing P = 2.84×10-6 (OR = 3.25, 95% CI = 1.95-5.41) 
(Table 2) (Supplementary Table S1) and P= 8.60×10-6 (OR = 3.70, 95% CI = 
2.10-6.68) when age and gender were adjusted. From the HLA class II region 
(Chr6: 32,256,456 – 33,258,648, GRCh37 hg19), including the HLA-DR gene 
which has been reported as a disease susceptibility gene for LP in the Italian 
population, the top hit association was observed at rs9461799 showing P = 
3.99×10-4 (OR = 2.15, 95% CI = 1.41-3.28) (Supplementary Figure 3) and 
age and gender adjusted P= 1.39×10-3 (OR = 2.20, 95% CI = 1.37-3.62). Here, 
susceptibility to or resistance against HCV related LP was evaluated by the 
OR for the minor allele (i.e. OR > 1 and OR < 1 indicate susceptible and 
resistant alleles, respectively). 
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We conducted a replication analysis of candidate SNPs associated with OLP 
or LP in Italian 45 subjects (Supplementary Table 2). The replication analysis 
in Italian subjects did not reach significant associations, but showed the same 
trend of ORs as shown in Japanese subjects. 
 
 
High-density association mapping based on genotype imputation 
 
Genotype imputation was carried out based on genome-wide SNP typing data 
using the phased genotype data of the 1000 Genomes Project reference data 
with IMPUTE2 software packages under default parameters. Among the genetic 
regions including SNPs with P <1x10-4 in the GWAS, two genetic regions 
included a SNP showing a stronger association in genotype imputation based 
high-density association mapping than the associations in GWAS (i.e. rs884000 
and rs538399) (Supplementary Figure 4). The SNP rs538399, showing P = 
6.50×10-5 (OR =0.40, 95% CI = 0.25-0.63) in the GWAS, is an intron variant of 
the insulin-like growth factor binding protein 4 (IGFBP4) gene. 
 
DISCUSSION 
One of the most important issues concerning OLP is its increased potential for 
malignant transformation into oral squamous cell carcinoma 2, 3. There is some 
evidence that HCV-positive OLP patients might be at higher risk of malignant 
transformation 27. The relative risk of malignant transformation for OLP patients 
with HCV, compared to those without HCV infection, was reported to be 3.16 27.  
 
The reported prevalence of HCV infected patients with LP shows wide 
geographical variation and is high in Japan and Italy 16, 17. We consider that the 
pathogenesis of OLP in HCV infection is not directly related to the virus itself, but 
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the response generated by host factors (e.g. immunological and genetic factors 
and insulin resistance). Previous reports indicated that there are no differences 
between HCV-infected patients with LP and those without in terms of viral factors, 
such as viral load, genotype/subtype and mutations leading to aa substitutions in 
the HCV core region (70 and/or 91) and IFN-sensitivity–determining region 
(ISDR) of nonstructural protein 5A (NS5A) 28, 29. 
 
A number of reports document the impact of IFN on HCV-associated OLP. As 
regards the effects of IFN therapy on LP lesions, there are reports of 
improvements in lesions, reports of LP manifestation triggered by IFN, and 
reports of exacerbation of LP. Especially, worsening pain and/or inflammation in 
OLP in patients receiving IFN therapy are particular problems which may result 
in the inability to complete IFN therapy. It remains difficult to predict the onset or 
exacerbation of OLP among HCV infected-patients. Most recently, we reported 
successful treatment of HCV-infected OLP by IFN-free therapy with direct-acting 
antivirals 30. 
 
We found no SNP with genome-wide significance (P <5×10-8). However, two 
SNPs (rs884000 in the NRP2 locus and rs538399 in the IGFBP4 locus) showed 
nominal associations in the GWAS and subsequent high-density association 
mapping. Moreover, our genetic analysis also supported the association of the 
HLA class II region, including HLA-DR and DQ genes, with HCV-positive OLP 18, 
19
. The two genetic loci found in our study and HLA genes could be useful as 
predictors for onset of OLP among HCV-infected patients. The replication study 
in Italian subjects showed the trend similar to Japanese results. 
 
Neuropilins (NRPs), including neuropilin-l (NRP1) and NRP2, are related 
transmembrane receptors that function as mediators of neuronal guidance and 
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angiogenesis. NRPs bind members of the class 3 semaphorin family (Sema3A, 
Sema3B, and Sema3C), regulators of neuronal guidance, and of the vascular 
endothelial growth factor (VEGF) family of angiogenesis factors 31. NRPs 
function in many key biological processes, including in the cardiovascular, 
nervous and immune systems 32. There is substantial evidence that NRPs serve 
as mediators of developmental and tumor angiogenesis 31. 
 
Recent evidence suggests that NRP2 is expressed in tumor tissue and plays a 
role in tumor progression and metastasis 33, 34. NRP2 is highly expressed on the 
surface of cancer cells from pancreatic neuroendocrine tumors 35, colorectal 
carcinomas 33, breast cancer 36, cutaneous melanoma 37 and oral squamous cell 
carcinoma (SCC) 38. NRP2 expression also correlates with lymph node 
metastasis in breast cancer 36 and papillary thyroid carcinoma 34. Cao et al. 
showed that NRP2 promotes metastasis of renal cell carcinoma (RCC) and 
pancreatic cancer in mouse and zebrafish models and showed a mechanism 
through which NRP2 expressed on cancer cells interacts with α5 integrin on 
endothelial cells to mediate vascular adhesion and extravasation 39.  
 
The insulin-like growth factor system (IGFs) consists of two peptides (IGF-I and 
-II), two main receptors (IGF-IR and IGFIIR), six different IGF binding proteins 
(IGFBP1-6) and four IGFBP related peptides (IGFBP Rp1-4). IGFs have multiple 
functions regarding cellular growth, survival and differentiation under different 
physiological and pathological conditions 40. IGFBP4 is an important member of 
the IGF system. IGFBP4 has been reported to play critical role in cardiomyocyte 
differentiation of embryonic stem cells (ESCs) 41.  
 
Several cancer cell lines, including from multiple myeloma, neuroblastoma and 
mesothelioma, and cancers of the lung, gastric, thyroid, breast, prostate and 
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colon, have been reported to express IGFBP4 42. Ueno et al. initially showed that 
the expression of IGFBP4 was significantly lower in primary RCC and higher in 
metastatic RCC, compared to normal human kidney tissue, and that IGFBP4 
transfectants promoted cell growth (in vitro and in vivo), invasion and motility in 
primary RCC 43. 
 
In the present study, four of 71 LP Japanese patients (5.6%), three women and 
one man, developed oral SCC. One of the four subjects was a 84-year-old 
woman who suffered from HCV-related liver cirrhosis. She developed oral 
verrucous carcinoma, arising OLP-coexisting vulvo-vaginal gingival syndrome 
and esophageal SCC 44. Another, in whom SVR was obtained by IFN therapy, 
was a 73-year-old man who suffered from chronic hepatitis C and hypertension. 
He developed tongue cancer and Graves' ophthalmopathy during pegylated IFN 
(Peg-IFN) plus ribavirin therapy. The third patient was a 57-year-old woman who 
suffered from chronic hepatitis C during IFN therapy. She developed tongue 
cancer arising from OLP. The fourth was a 67-year-old woman who suffered 
from chronic hepatitis C. She developed tongue cancer arising from OLP after 
treatment with Peg-IFN plus ribavirin. Only she had the risk allele at rs88400 in 
NRP2 but she did not have the resistance allele at rs538399 in IGFBP4. No 
patients in the control group developed oral cancer. 
 
We reported previously that insulin resistance might be involved in the 
development of multiple primary cancers in patients with oral SCC and HCV 
infection 45 and might cause OLP and extrahepatic manifestations 46, 47. The 
prevalence of extrahepatic malignant tumors was significantly higher in patients 
with OLP (29.4%) than in patients without (4.3%) 47. Two SNPs (rs884000 on 
NRP2 and rs538399 on IGFBP4) may play a role in the malignant transformation 
of OLP.  
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Our study had some limitations. The sample size was relatively smaller than that 
for the conventional GWAS for diagnostic criteria. However, to the best of our 
knowledge, our GWAS for HCV-related LP is the first such report.  
 
In conclusion, we identified novel associations of rs884000 in NRP2, rs538399 
on IGFBP4, and supported the association of the HLA-DR/DQ genes, with 
HCV-positive LP in the Japanese and Italian population. Our data suggest that 
these genes may be involved in the development of LP and malignant 
transformation and useful as a predictive marker for the onset of OLP with IFN 
therapy among HCV infected-patients.   
 
ACKNOWLEDGEMENTS 
We thank Dr. Shintaro Ogawa (Department of Virology, Liver Unit, Nagoya City 
University Graduate School of Medical Sciences) for disposal of samples. We 
also thank Dr. Minae Kawashima, Dr. Hiromi Sawai, Ms. Yuko 
Ogasawara-Hirano, Natsumi Baba, Rieko Shirahashi, Ayumi Nakayama and 
Megumi Yamaoka-Sageshima (University of Tokyo), and Ms. Yoriko Mawatari, 
Mayumi Ishii, Takayo Tsuchiura (National Center for Global Health and 
Medicine) for technical assistance. We also thank Dr. Francesca Bertinetto and 
Dr. Ennia Dametto (Regional Transplantation Center, Piedmont, Molinette 
Hospital) for collection of samples.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
Figure legends 
 
Figure 1: Clinical presentations of lichen planus (Panel A, lower lip; Panel B and 
D, left buccal mucosa; Panel C, tongue) 
 
Figure 2: Genome-wide view of the single-point association data based on allele 
frequencies in a comparison of 71 HCV Japanese patients with LP and 
190 HCV patients without OLP. P values were calculated using the 
chi-square test for allele frequencies among 629,553 SNPs. 
 
 
 
 
 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
References 
1. Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 cases. 
Oral Surg Oral Med Oral Pathol 1968;25:31-42. 
2. Eisen D, Carrozzo M, Bagan Sebastian JV, et al. Number V Oral lichen 
planus: clinical features and management. Oral Dis 2005;11:338-49. 
3. Eisen D. The clinical features, malignant potential, and systemic 
associations of oral lichen planus: a study of 723 patients. J Am Acad 
Dermatol 2002;46:207-14. 
4. Jungell P, Konttinen YT, Nortamo P, et al. Immunoelectron microscopic 
study of distribution of T cell subsets in oral lichen planus. Scand J Dent 
Res 1989;97:361-7. 
5. Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in 
lichen planus. Br J Dermatol 2000;142:449-56. 
6. Payeras MR, Cherubini K, Figueiredo MA, et al. Oral lichen planus: focus 
on etiopathogenesis. Arch Oral Biol 2013;58:1057-69. 
7. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of 
extrahepatic manifestations. Ann Intern Med 1995;123:615-20. 
8. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C 
virus chronic active hepatitis: a prospective case-control study. 
Hepatology 1994;19:841-8. 
9. El-Serag HB, Hampel H, Yeh C, et al. Extrahepatic manifestations of 
hepatitis C among United States male veterans. Hepatology 
2002;36:1439-45. 
10. Nagao Y, Sata M, Noguchi S, et al. Detection of hepatitis C virus RNA in 
oral lichen planus and oral cancer tissues. J Oral Pathol Med 
2000;29:259-66. 
11. Carrozzo M, Quadri R, Latorre P, et al. Molecular evidence that the 
hepatitis C virus replicates in the oral mucosa. J Hepatol 2002;37:364-9. 
12. Pilli M, Penna A, Zerbini A, et al. Oral lichen planus pathogenesis: A role 
for the HCV-specific cellular immune response. Hepatology 
2002;36:1446-52. 
13. Shengyuan L, Songpo Y, Wen W, et al. Hepatitis C virus and lichen 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
planus: a reciprocal association determined by a meta-analysis. Arch 
Dermatol 2009;145:1040-7. 
14. Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen 
planus: a systematic review with meta-analysis. Oral Dis 2010;16:601-12. 
15. Petti S, Rabiei M, De Luca M, et al. The magnitude of the association 
between hepatitis C virus infection and oral lichen planus: meta-analysis 
and case control study. Odontology 2011;99:168-78. 
16. Nagao Y, Sata M, Tanikawa K, et al. Lichen planus and hepatitis C virus in 
the northern Kyushu region of Japan. Eur J Clin Invest 1995;25:910-4. 
17. Carrozzo M, Gandolfo S, Carbone M, et al. Hepatitis C virus infection in 
Italian patients with oral lichen planus: a prospective case-control study. J 
Oral Pathol Med 1996;25:527-33. 
18. Carrozzo M, Francia Di Celle P, Gandolfo S, et al. Increased frequency of 
HLA-DR6 allele in Italian patients with hepatitis C virus-associated oral 
lichen planus. Br J Dermatol 2001;144:803-8. 
19. Carrozzo M, Brancatello F, Dametto E, et al. Hepatitis C virus-associated 
oral lichen planus: is the geographical heterogeneity related to HLA-DR6? 
J Oral Pathol Med 2005;34:204-8. 
20. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for 
hepatocellular carcinoma in chronic hepatitis C virus infection. 
Hepatology 2010;52:518-27. 
21. Nagao Y, Sata M, Ide T, et al. Development and exacerbation of oral 
lichen planus during and after interferon therapy for hepatitis C. Eur J Clin 
Invest 1996;26:1171-4. 
22. Schlesinger TE, Camisa C, Gay JD, et al. Oral erosive lichen planus with 
epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic 
hepatitis C virus infection. J Am Acad Dermatol 1997;36:1023-5. 
23. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts 
hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401. 
24. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of 
IL28B with response to pegylated interferon-alpha and ribavirin therapy 
for chronic hepatitis C. Nat Genet 2009;41:1105-9. 
25. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat 
Genet 2009;41:1100-4. 
26. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against 
anaemia in patients treated for chronic hepatitis C. Nature 
2010;464:405-8. 
27. Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell 
carcinoma in 402 patients with oral lichen planus: a follow-up study in an 
Italian population. Oral Oncol 2004;40:77-83. 
28. Nagao Y, Sata M, Itoh K, et al. Quantitative analysis of HCV RNA and 
genotype in patients with chronic hepatitis C accompanied by oral lichen 
planus. Eur J Clin Invest 1996;26:495-8. 
29. Nagao Y, Sata M. A retrospective case-control study of hepatitis C virus 
infection and oral lichen planus in Japan: association study with mutations 
in the core and NS5A region of hepatitis C virus. BMC Gastroenterol 
2012;12:31. 
30. Nagao Y, Kimura K, Kawahigashi Y, et al. Successful Treatment of 
Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free 
Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol 
2016;7:e179. 
31. Bagnard D. Neuropilin: From Nervous System to Vascular and Tumor 
Biology Adv Exp Med Bioi 2002;515:33-48. 
32. Parker MW, Guo HF, Li X, et al. Function of members of the neuropilin 
family as essential pleiotropic cell surface receptors. Biochemistry 
2012;51:9437-46. 
33. Gray MJ, Van Buren G, Dallas NA, et al. Therapeutic targeting of 
neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J 
Natl Cancer Inst 2008;100:109-20. 
34. Yasuoka H, Kodama R, Hirokawa M, et al. Neuropilin-2 expression in 
papillary thyroid carcinoma: correlation with VEGF-D expression, lymph 
node metastasis, and VEGF-D-induced aggressive cancer cell phenotype. 
J Clin Endocrinol Metab 2011;96:E1857-61. 
35. Cohen T, Herzog Y, Brodzky A, et al. Neuropilin-2 is a novel marker 
expressed in pancreatic islet cells and endocrine pancreatic tumours. J 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
Pathol 2002;198:77-82. 
36. Yasuoka H, Kodama R, Tsujimoto M, et al. Neuropilin-2 expression in 
breast cancer: correlation with lymph node metastasis, poor prognosis, 
and regulation of CXCR4 expression. BMC Cancer 2009;9:220. 
37. Rossi M, Tuck J, Kim OJ, et al. Neuropilin-2 gene expression correlates 
with malignant progression in cutaneous melanoma. Br J Dermatol 
2014;171:403-8. 
38. Zhang B, Gao Z, Sun M, et al. Prognostic significance of VEGF-C, 
semaphorin 3F, and neuropilin-2 expression in oral squamous cell 
carcinomas and their relationship with lymphangiogenesis. J Surg Oncol 
2015;111:382-8. 
39. Cao Y, Hoeppner LH, Bach S, et al. Neuropilin-2 promotes extravasation 
and metastasis by interacting with endothelial alpha5 integrin. Cancer 
Res 2013;73:4579-90. 
40. Zhou R, Diehl D, Hoeflich A, et al. IGF-binding protein-4: biochemical 
characteristics and functional consequences. J Endocrinol 
2003;178:177-93. 
41. Xue Y, Yan Y, Gong H, et al. Insulin-like growth factor binding protein 4 
enhances cardiomyocytes induction in murine-induced pluripotent stem 
cells. J Cell Biochem 2014;115:1495-504. 
42. Durai R, Davies M, Yang W, et al. Biology of insulin-like growth factor 
binding protein-4 and its role in cancer (review). Int J Oncol 
2006;28:1317-25. 
43. Ueno K, Hirata H, Majid S, et al. IGFBP-4 activates the Wnt/beta-catenin 
signaling pathway and induces M-CAM expression in human renal cell 
carcinoma. Int J Cancer 2011;129:2360-9. 
44. Nagao Y, Sata M. Oral verrucous carcinoma arising from lichen planus 
and esophageal squamous cell carcinoma in a patient with hepatitis C 
virus-related liver cirrhosis-hyperinsulinemia and malignant 
transformation: A case report. Biomed Rep 2013;1:53-56. 
45. Nagao Y, Sata M. High incidence of multiple primary carcinomas in 
HCV-infected patients with oral squamous cell carcinoma. Med Sci Monit 
2009;15:Cr453-9. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
46. Nagao Y, Kawaguchi T, Tanaka K, et al. Extrahepatic manifestations and 
insulin resistance in an HCV hyperendemic area. Int J Mol Med 
2005;16:291-6. 
47. Nagao Y, Kawasaki K, Sata M. Insulin resistance and lichen planus in 
patients with HCV-infectious liver diseases. J Gastroenterol Hepatol 
2008;23:580-5. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. Characteristics of studied Japanese population (n=261)
Characteristics Total Case Control
P value
No. subjects 261 71 190
Sex male / female 107 / 154 24 / 47 83 / 107 NS
Age  (mean ± SD), years 61.8 ± 10.4 67.2 ± 9.6 59.8 ± 10.0 <0.0001
Site of lichen 
planus Oral mucosa 65
Oral & genital  mucosa 1
Oral mucosa & skin 3
Skin 2
Diagnosis of liver 
diseases Past history of HCV infection 2 0.77% 1 1.41% 1 0.53%
AH-C post IFN (SVR) 2 0.77% 0 0.00% 2 1.05%
CH-C 170 65.13% 40 56.34% 130 68.42%
CH-C post IFN (SVR) 23 8.81% 8 11.27% 15 7.89%
CH-C post IFN (SVR) &  
NAFLD 1 0.38% 0 0.00% 1 0.53%
CH-C post IFN (SVR)  &  
Asymptomatic HBV carrier 1 0.38% 0 0.00% 1 0.53%
CH-C &  AIH 1 0.38% 0 0.00% 1 0.53%
CH-C &  ALD 1 0.38% 0 0.00% 1 0.53%
CH-C &  HCV-related HCC 16 6.13% 6 8.45% 10 5.26%
CH-C & CH-B & HCC 2 0.77% 0 0.00% 2 1.05%
CH-C post IFN (SVR) &   
HCV-related HCC 1 0.38% 0 0.00% 1 0.53%
LC-C 19 7.28% 6 8.45% 13 6.84%
LC-C & AIH 1 0.38% 1 1.41% 0 0.00%
LC-C & post IFN (SVR) 1 0.38% 0 0.00% 1 0.53%
LC-C & HCV-related HCC 20 7.66% 9 12.68% 11 5.79%
with lichen planus with normal oral mucosa
AH-C, acute hepatitis C; CH-C, chronic hepatitis C; IFN, interferon: SVR, sustained virological response; NAFLD, Non-
alcoholic fatty liver disease; AIH, Autoimmune hepatitis; ALD, Alcoholic liver disease; LC-C, liver cirrhosis type C; HCC, 
hepatocellular carcinoma 
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Table 2. Associations of rs884000 with HCV-related lichen planus
Physical Position 
rs ID Chr. (build 37/Hg19) P -value
a
OR
b Low High AA AB BB No Call MAF AA AB BB No Call MAF Associated Gene
rs884000 2 206680397 2.84E-06 3.25 1.95 5.41 3 30 38 0 0.25 3 30 157 0 0.09 G T NRP2
a
P value of Pearson’s chi-square test for allelic model.
b
Odds ratio (OR) of minor allele from two-by-two allele frequency table
Susceptibility to or resistance against HCV related LP was evaluated by the OR for minor allele (i.e. OR > 1 and OR < 1 indicate susceptible and resistant alleles, respectively).
95%CI Case Control 
Allele A Allele B 
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sTable 1. Associations of genome-wide association study for HCV-related lichen planus cases and controls: GWAS result_P value<10-4
Physical Position 
rs ID Chr. (build 37/Hg19) P -value
a
OR
b Low High AA AB BB No Call MAF AA AB BB No Call MAF Associated Gene
rs241501 1 49765438 5.49E-05 0.39 0.25 0.62 1 26 44 0 0.20 31 84 75 0 0.38 G T AGBL4
rs568052 1 55524842 6.37E-05 0.18 0.07 0.46 0 5 66 0 0.04 4 56 130 0 0.17 C T PCSK9
rs10915880 1 224041034 1.41E-05 4.87 2.24 10.59 3 12 56 0 0.13 1 9 180 0 0.03 A G TP53BP2
rs17363620 2 5734639 4.59E-05 3.18 1.78 5.67 1 25 45 0 0.19 0 26 163 1 0.07 A T intergenic region
rs16863981 2 5736321 4.18E-05 3.20 1.79 5.70 1 25 45 0 0.19 0 26 164 0 0.07 A T intergenic region
rs13019074 2 5737785 8.39E-05 3.09 1.72 5.53 1 24 45 1 0.19 0 26 163 1 0.07 A C intergenic region
rs11693312 2 5745057 2.51E-05 2.92 1.75 4.88 1 32 38 0 0.24 1 35 154 0 0.10 A G intergenic region
rs6432151 2 5760116 4.54E-05 2.73 1.66 4.49 1 34 36 0 0.25 1 40 149 0 0.11 A T intergenic region
rs1437040 2 5760247 4.54E-05 2.73 1.66 4.49 1 34 36 0 0.25 1 40 149 0 0.11 A G intergenic region
rs6710579 2 5762278 7.94E-05 2.67 1.62 4.39 1 33 36 1 0.25 1 40 148 1 0.11 G T intergenic region
rs7610518 3 46161631 7.09E-05 0.41 0.27 0.64 3 26 42 0 0.23 30 97 63 0 0.41 C T XCR1
rs4859240 3 182476614 9.38E-05 0.40 0.25 0.64 3 21 47 0 0.19 29 81 78 2 0.37 A G intergenic region
rs11943343 4 117407994 9.30E-05 5.06 2.07 12.34 1 12 58 0 0.10 0 8 181 1 0.02 A G intergenic region
rs13148375 4 177557439 6.03E-05 2.88 1.69 4.90 2 27 41 1 0.22 3 28 158 1 0.09 A C intergenic region
rs2067833 6 53330356 3.51E-05 2.33 1.55 3.49 16 30 25 0 0.44 14 67 109 0 0.25 A G intergenic region
rs2189887 8 5501607 3.25E-05 0.23 0.11 0.48 0 8 63 0 0.06 8 63 118 1 0.21 A T intergenic region
rs391583 8 37178897 4.37E-05 0.36 0.22 0.60 1 20 50 0 0.15 26 76 88 0 0.34 C T intergenic region
rs6995149 8 37179494 3.50E-05 0.36 0.22 0.59 1 20 50 0 0.15 27 75 88 0 0.34 C G intergenic region
rs436802 8 37180035 2.33E-05 0.34 0.21 0.57 1 19 50 1 0.15 27 75 88 0 0.34 C T intergenic region
rs7865508 9 332639 8.51E-05 2.54 1.58 4.09 6 27 38 0 0.27 3 43 143 1 0.13 C T DOCK8
rs7870726 9 13530105 5.89E-05 3.18 1.77 5.73 4 18 49 0 0.18 1 23 166 0 0.07 C T intergenic region
rs12343442 9 15212216 5.44E-05 4.70 2.08 10.62 1 14 56 0 0.11 0 10 180 0 0.03 G T TTC39B
rs7087214 10 106193598 7.40E-05 2.59 1.60 4.19 5 28 38 0 0.27 5 37 148 0 0.12 A C CCDC147
rs8181424 10 128602101 8.96E-05 2.32 1.51 3.55 9 33 29 0 0.36 2 70 118 0 0.19 C T DOCK1
rs7294533 12 54612774 6.06E-05 2.75 1.66 4.58 6 22 43 0 0.24 2 35 153 0 0.10 C T CBX5
rs7315138 12 62388915 6.90E-05 2.24 1.50 3.34 18 28 25 0 0.45 13 76 101 0 0.27 A T FAM19A2
rs202092 13 30814313 9.82E-05 4.15 1.93 8.93 1 15 55 0 0.12 0 12 177 1 0.03 C T KATNAL1
rs7140779 14 49946421 3.64E-05 2.50 1.60 3.88 10 27 31 3 0.35 5 56 128 1 0.17 C T intergenic region
rs11624787 14 53288450 6.27E-05 0.42 0.27 0.65 4 27 40 0 0.25 34 96 57 3 0.44 C G FERMT2
95%CI Case Control 
Allele A Allele B 
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rs538399 17 38610665 6.50E-05 0.40 0.25 0.63 2 25 42 2 0.21 26 99 64 1 0.40 C T IGFBP4
rs3862706 18 57728033 6.09E-05 4.31 2.00 9.28 1 15 53 2 0.12 0 12 178 0 0.03 G T intergenic region
rs4812826 20 42972275 8.26E-05 2.18 1.47 3.23 23 37 11 0 0.58 28 93 69 0 0.39 A G R3HDML
rs5997363 22 28794069 1.25E-05 7.56 2.64 21.61 2 9 60 0 0.09 0 5 185 0 0.01 A G TTC28
rs713727 22 49794342 7.44E-05 3.73 1.87 7.43 0 20 51 0 0.14 1 14 175 0 0.04 C T intergenic region
a
P value of Pearson’s chi-square test for allelic model.
b
Odds ratio (OR) of minor allele from two-by-two allele frequency table
Susceptibility to or resistance against HCV related LP was evaluated by the OR for minor allele (i.e. OR > 1 and OR < 1 indicate susceptible and resistant alleles, respectively).
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sTable 2. Replication study of rs9461799, rs538399, and rs884000 with HCV-related lichen planus in Italian patients
Physical Position 
rs ID Chr. (build 37/Hg19) P -value
a
OR
b Low High AA AB BB No Call RAF AA AB BB No Call RAF Associated Gene
rs9461799 6 32689529 4.74E-01 1.57 5.42 0.454 12 13 10 3 0.53 1 3 2 0 0.42 T C HLA class II
rs538399 17 38610665 9.14E-01 0.91 4.81 0.173 0 13 22 3 0.19 0 2 3 2 0.20 G A IGFBP4
rs884000 2 206680397 7.95E-01 1.33 11.7 0.152 1 6 30 1 0.11 0 1 5 1 0.08 C A NRP2
a
P value of Pearson’s chi-square test for allelic model.
b
Odds ratio (OR) of minor allele from two-by-two allele frequency table
Susceptibility to or resistance against HCV related LP was evaluated by the OR for minor allele (i.e. OR > 1 and OR < 1 indicate susceptible and resistant alleles, respectively).
95%CI Case Control 
Allele A Allele B 
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